Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.
Future Oncol
; 12(6): 779-87, 2016 Mar.
Article
en En
| MEDLINE
| ID: mdl-26829128
ABSTRACT
AIMS:
Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. PRIMARYOBJECTIVE:
raising the clinical complete response rate from 5 to 25%. SECONDARYOBJECTIVES:
toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients.RESULTS:
Results on 18 patients are reported. Specifically considering irradiated sites 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range 8-50), 7/18 patients progressed in irradiated sites.CONCLUSION:
Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
/
Protocolos de Quimioterapia Combinada Antineoplásica
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2016
Tipo del documento:
Article
País de afiliación:
Italia